Commentary
Second QUARTER 2009
ECONOMICS
stimulus injected into the economy by the U.S. governments various bailouts has, on the other hand, caused many prognosticators to warn of coming 1970s-style inflation. It is as if Goldilocks cannot make up her mind: is the economy going to be too hot, too cold or just right?
: : Is It Safe to Go Back in the Water? : : Fixed Income Dilemma: Wheres the Yield?
FEATURED EQUITY
with the paltry short-term yields. Our stock selections will favor companies that skillfully employ prudent amounts of debt in their capital structures, and move away from extremely low or no-debt businesses. Specifically, we are looking for companies with long-term fixed debt that has been used to finance plant and equipment; we will avoid companies with short-term debt or liabilities connected with consumer finance. Finally, we are prospecting for holdings that will allow us to offset any potential decline in the U.S. dollar.
CASH POSITION
30.0% 25.0%
: : Varian Medical
WEALTH MANAGEMENT
modestly. We have concluded that deflation is now a small risk. Consequently, we have lowered the percentage of cash in our portfolios. To take the deflation card off the table, the Fed dramatically
DOW LEVEL
% CASH
www.nelsonroberts.com | 650.322.4000
Our approach today is to take pru portfolios and keep fixed income m
ASSET MANAGEMENT
CIsCo systems
IshaRes
ChevRon CoRP GIlead sCIenCes oRaCle CoRP adobe systems masteRs seleCt Intl Fund Fastenal sChlumbeRGeR utIlItIes seCtoR sPdR tJx ComPanIes mICRosoFt texas InstRuments theRmo FIsheR sCIentIFIC
www.nelsonroberts.com | 650.322.4000
udent risks on the equity side of our money short, secure and liquid.
to 12%. We anticipate that our next purchases will be from our back shelf company list. These companies have a greater propensity to use debt, and therefore were hammered in a market fretting about deflation. They should rebound as these fears recede. Recent decisions by technology leaders Microsoft and Cisco to use leverage on their balance sheets reflect this change in thinking, and should boost earnings.
yielding 2.2%, the total return on that bond through 6/30/09 would have been -8.7%, as interest rates increased to 3.5%. We believe the best options for fixed income investment in this environment include the following: 1. Short CDs (1-3 years): currently the best alternative to Treasurys. CD yields average about 0.75% higher than Treasurys, are FDIC-insured for amounts up to $250,000 (this limit has been extended to December 2014) and have decent liquidity if an investor needs to sell before maturity. 2. Investment-grade corporate bonds: credit spreads for these bonds have tightened as the economic landscape has improved in recent months. There are still some opportunities, but with default rates yet to peak and yields close to levels obtainable through CDs, risks and rewards need to be carefully weighed. 3. Municipal bonds: yields are attractive, but higher rates reflect the financial difficulties facing many states. This is especially true for the state of California, which has seen borrowing costs increase as legislators attempt to close a staggering budget gap. We will be taking a close look at a new type of municipal bond called the Build America Bond (BAB) which emerged from the American Recovery and Reinvestment Act of 2009. These are taxable bonds issued by state and local municipalities that are partially subsidized by the federal government. Forecasting interest rates is always challenging, but is especially so right now because of the uncertain downstream effects of the stimulus. Our approach today is to take prudent risks on the equity side of our portfolios and keep fixed income money short, secure and liquid.
integrity
12/31/2008 6/30/2009
This graph demonstrates the convergence of prices between 10-year and 30-year bonds over six months, emphasizing the importance of keeping fixed-income investments short-term.
FEATURED EQUITY
Varian Medical
Varian is a leading provider of radiation therapy machines and software to treat cancer. The companys products include linear accelerators (radiotherapy), equipment that allows neurosurgeons to visualize and operate in three dimensions using external beam radiation (stereotactic radiosurgery) and radioactive seeds that are temporarily implanted in a cancerous tumor (brachytherapy). The company also designs, manufactures and sells X-ray machines that use film and those that use flat panel digital image detectors for filmless X-ray systems. In the last several years, Varian has entered the security screening business, which uses similar technology. Radiation therapy is used to treat a wide variety of solid tumors, including cancers of the head and neck, breast, prostate, pancreas, lung, liver, uterus, ovary, brain and spinal cord. Varians intensity-modulated radiation therapy (IMRT) allows the shape, intensity and angle of the beam from the linear accelerator to conform better to the shape of the tumor, thus decreasing radiation to surrounding, normal tissue. The companys image-guided radiation therapy (IGRT) further refines this process. Varians RapidArc machine and associated software continue to experience strong demand world-wide. Treatments are faster and more effective for patients and healthcare centers can treat many more people per day. The aging population, increased incidence of smoking in developing countries and unhealthy lifestyles are all driving an increase in the number of cancer cases around the world. Healthcare authorities project an increase of 50%, to 15 million cases, by 2020. Many countries remain woefully under-equipped to treat cancer with radiotherapy, providing significant untapped markets for Varian. While Varian has experienced some slowdown in orders during the recession, revenues continue to grow and 300 new orders for RapidArc were booked in 2008. The company has a solid balance sheet with minimal debt. We believe Varians technological leadership, strong management and prudent financial position will result in steady growth over the next several years. Recessions resolve, and as this one does, healthcare organizations will again be looking to upgrade to the most effective and efficient ways to treat patients with cancer.
Index RetuRns
EAFE (international stocks) Russell 2000 (small stocks) Barclays International Barclays Municipal
WEALTH MANAGEMENT
The Nelson Roberts Investment Advisors quarterly commentary will be available electronically in future quarters. If you would like to continue to receive this piece in hard copy, please contact Tien Tran at ttran@nelsonroberts.com
www.nelsonroberts.com | 650.322.4000
Investment Team
Brooks Nelson, CFA Brian Roberts, CFA, MBA Steve Philpott, MBA Dennistoun Brown, MD Ann Oglesby, MD, MBA
WEALTH MANAGEMENT
Some examples from research on overconfidence: 19% of people think they belong to the richest 1% of U.S. households. 82% of people say they are in the top 30% of safe drivers. 80% of students think they will finish in the top half of their class. 68% of lawyers in civil cases believe that their side will prevail. 81% of new business owners think their business has at least a
70% chance of success, but only 39% think any business like theirs would be likely to succeed.
Past performance is not necessarily a guide to future performance. There are risks involved in investing, including possible loss of principal. This information is provided for informational purposes only and does not constitute a recommendation for any investment strategy, security or product described herein. Please contact us for a complete list of portfolio holdings. For additional information on the services of Nelson Roberts Investment Advisors, or to receive our Newsletters via e-mail or be removed from our mailing list, please contact us at 650-322-4000.
1950 University Avenue, Suite 202 East Palo Alto, CA 94303 tel 650-322-4000 web www.nelsonroberts.com email invest@nelsonroberts.com